VivoSeq
Oncology

Metastatic Colon Cancer

0

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Metastatic Colon Cancer is an early-stage landscape with 0 programs across 4 companies. The most active players are Amgen, ARCA Biopharma, Inc., Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

64/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalA

ARCA Biopharma, Inc.

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalO

Oncozyme Pharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Unknown status3 · 19%
Terminated2 · 13%
Not yet recruiting1 · 6%
Recruiting1 · 6%
Withdrawn1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

16 trials

Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
Recruiting·—·Phase 2·NCT05870800·28 enrolled
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
Not yet recruiting·—·Phase 2·NCT07224022·24 enrolled
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Completed·Amgen logoAmgen·Phase 2·NCT00094809·252 enrolled
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03428126·29 enrolled
Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI
Completed·HHanoi Medical University·N/A·NCT03504618·39 enrolled
TAS-OX for Refractory Metastatic Colon Cancer
Completed·YYale University·Phase 1/2·NCT02848079·41 enrolled
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Completed·MMt. Sinai Medical Center, Miami·Phase 2·NCT00625573·29 enrolled
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00612586·117 enrolled
A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment
Completed·OOncozyme Pharma Inc.·Phase 1/2·NCT00809796·15 enrolled
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Suspended·AARCA Biopharma, Inc.·Phase 1/2·NCT00443573·100 enrolled
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
Terminated·UUniversity of Miami·Phase 2·NCT00276861·10 enrolled
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
Terminated·National Cancer Institute (NCI)·Phase 2·NCT00397878·10 enrolled
Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
Withdrawn·IInstitut Bergonié·Phase 1·NCT02774512
Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer
Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT00295035·100 enrolled
The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer
Unknown status·FFudan University·Phase 3·NCT04416854·627 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)